0001423173-13-000002.txt : 20130327
0001423173-13-000002.hdr.sgml : 20130327
20130327163159
ACCESSION NUMBER: 0001423173-13-000002
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: Rule 506
FILED AS OF DATE: 20130327
DATE AS OF CHANGE: 20130327
EFFECTIVENESS DATE: 20130327
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROPHAGE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001423173
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-194074
FILM NUMBER: 13720344
BUSINESS ADDRESS:
STREET 1: 222 THIRD STREET, SUITE 3120
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 1-617-714-5468
MAIL ADDRESS:
STREET 1: 222 THIRD STREET, SUITE 3120
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
D
1
primary_doc.xml
X0706
D
LIVE
0001423173
NEUROPHAGE PHARMACEUTICALS INC
222 THIRD STREET, SUITE 3120
CAMBRIDGE
MA
MASSACHUSETTS
02142
1-617-714-5468
DELAWARE
None
None
Corporation
true
Hampus
Hillerstrom
c/o NeuroPhage Pharmaceuticals, Inc.
222 Third Street, Suite 3120
Cambridge
MA
MASSACHUSETTS
02142
Executive Officer
Vicki
Sato
c/o NeuroPhage Pharmaceuticals, Inc.
222 Third Street, Suite 3120
Cambridge
MA
MASSACHUSETTS
02142
Director
Jonathan
Solomon
c/o NeuroPhage Pharmaceuticals, Inc.
222 Third Street, Suite 3120
Cambridge
MA
MASSACHUSETTS
02142
Executive Officer
Director
John
Dee
c/o NeuroPhage Pharmaceuticals, Inc.
222 Third Street, Suite 3120
Cambridge
MA
MASSACHUSETTS
02142
Director
Paul
Goldenheim
c/o NeuroPhage Pharmaceuticals, Inc.
222 Third Street, Suite 3120
Cambridge
MA
MASSACHUSETTS
02142
Director
Valerie
Calenda
c/o NeuroPhage Pharmaceuticals, Inc.
222 Third Street, Suite 3120
Cambridge
MA
MASSACHUSETTS
02142
Director
Kenneth
Buckfire
c/o NeuroPhage Pharmaceuticals, Inc.
222 Third Street, Suite 3120
Cambridge
MA
MASSACHUSETTS
02142
Director
Biotechnology
Decline to Disclose
- 06
false
2013-03-14
false
true
true
true
false
0
8256229
3669479
4586750
false
31
0
0
0
false
NEUROPHAGE PHARMACEUTICALS INC
/s/ Hampus Hillerstrom
Hampus Hillerstrom
Executive Vice President
2013-03-27